Rita Nanda to Mutation
This is a "connection" page, showing publications Rita Nanda has written about Mutation.
Connection Strength
0.152
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.028
-
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
Score: 0.024
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.021
-
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 20; 38(36):4274-4282.
Score: 0.020
-
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat. 2018 Oct; 171(3):637-648.
Score: 0.017
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.016
-
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers. Breast Cancer Res Treat. 2017 Nov; 166(1):179-184.
Score: 0.016
-
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
Score: 0.011